Skip to content

Role of Proteomics in Diagnosing Sarcoidosis

Proteomics as a Tool for Biomarker Detection in Sarcoidosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00626938
Enrollment
1000
Registered
2008-02-29
Start date
2005-03-31
Completion date
2012-03-31
Last updated
2012-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoidosis

Keywords

sarcoidosis, protein profile, CYP-450, TNF-alpha polymorphisms, HLA

Brief summary

Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.

Interventions

None listed

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of pulmonary sarcoidosis stage I-IV

Exclusion criteria

* Non-smoking * No treatment for extra-pulmonary symptoms of sarcoidosis

Design outcomes

Primary

MeasureTime frame
protein profile in bloodwithin 1 month after obtaining sample

Secondary

MeasureTime frame
CYP and TNF polymorphismswithin 6 months after obtaining sample

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026